Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer

In conclusion, the incidence of AI among NSCLC patients treated with anti-PD-1 antibodies was similar to previous studies. Corticosteroid replacement improved PS, symptoms, and laboratory data of patients with AI and suspicious of AI. Corticosteroid replacement may contribute to continuation of anti-PD-1 antibodies and survival outcome was preferable in patients with AI and suspicious of AI receiving corticosteroid treatment.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research